Hemab Therapeutics (NASDAQ:COAG) Stock Rating Raised to Strong-Buy at Rodman & Renshaw

Hemab Therapeutics (NASDAQ:COAG) was upgraded by analysts at Rodman & Renshaw to a “strong-buy” rating in a report released on Monday, Zacks reports.

Other research analysts have also issued research reports about the company. Wedbush boosted their price target on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Jefferies Financial Group increased their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a report on Monday, July 13th. HC Wainwright raised their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings downgraded shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.17.

Hemab Therapeutics Stock Performance

COAG opened at $29.80 on Monday. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $55.42. The stock’s 50-day moving average is $42.06.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.17). Equities research analysts predict that Hemab Therapeutics will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Hemab Therapeutics

Hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC bought a new position in Hemab Therapeutics during the second quarter worth about $230,000. The Manufacturers Life Insurance Company acquired a new position in Hemab Therapeutics during the second quarter worth approximately $688,000. Opaleye Management Inc. bought a new stake in Hemab Therapeutics in the second quarter valued at approximately $1,750,000. State Street Corp bought a new stake in Hemab Therapeutics in the second quarter valued at approximately $2,825,000. Finally, Braidwell LP bought a new stake in Hemab Therapeutics in the second quarter valued at approximately $5,877,000.

About Hemab Therapeutics

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.